CITATION OF PRIOR AF

Sheet 1 of 6 1 U J 1773

	Ind 0	
FORM PT0-1449 U.S. DEPARTMENT OF COMM	FERCE ATTY. DOCKET NO.	APPLICATION SERIAL NO. 1 FROM
(REV. 8-83) PATENT AND TRADEMARK C	PT-1039	APPLICATION SERIAL NO. 1500
INFORMATION DISCLOSURE CITATION. (Use several sheets if necessary)	ON APPLICANTS Rudolph E. Falk,	Samuel S. Asculai,
	FILING DATE Jan. 14, 1995	1806 1211

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Xu	2,583,096	01 1952	Hadidian et al			
الم	3,436,454	04-1969	Nouvel			
	3,887,703	06-1975	Manoussos et al			
	4,272,522	06-1981	Balazs			
	4,716,224	12-1987	Sakurai et al.	-		
	4,853,226	08-1989	Machida et al.	·		
	4,946,870	08-1990	Partain, III. et al.	_		
FOREIG	N PATENT DOCUMENT	ΓS			Sub-	
	Document No.	Date	Country	Class	Class	YES NO
181	B-72117/87	12-1987	Australia		- 53	
%	30806/84	07-1984	Australia	<u>.</u>		
Xa-	0,378,852	12-1989	Europe			
			,			
Jec.	1,283,892	08-1972	Great Britain			
9/1	2,099,826-A	12-1982	Great Britain	·		
\ 04	A-116678/88	11-1989	Japan			Yes
SPIL	Application	Laid-Open-to-Public	_			
$\sqrt{1-1}$	61-233,622	10-1986	Japan w	1 con	ade	No
XV	57-183,707	12-1982	Japan	~		Yes
0			\			
Jan 1	2,364,373	10-1975	Germany			Yes

KILIKOWA~ 5/10/95

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION (Use several	Sheets if necessary	APPLICANTS Rudolph E. Falk,	Samuel S. Asculai
•	7595 CARL COM	FILING DATE Jan. 14, 1995	GROUP 1806 1211

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


Xr.	Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
	Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. Volumes III. New York: Academic Press, 1970. PP. 1241-1253.
	Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
	Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
	Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6): 779-784.
	Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. Dissertation Abstracts International 1988; 49(2): 367-B.

KRIKORIAN 5/10/95

FORM PT0-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	APPLICATION SERIAL NO.
REV. 8-83)	PATENT AND TRADEMARK OFFICE	PT-1039	07/838,675
NEORMATION	N DISCLOSURE CITATION	ARPLICANTS	
	sheets if necessary)	Ridolph E. Falk,	Samuel S. Asculai
	OFF.	Jan. 14, 1995	GROUP 1806 1211

SK	Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); Vol. 111: 520-521
	Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. Arch. Immunol. Ther. Exp. (1980); 28 (3): 439-446
	Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 384-388.
	Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. Arthritis and Rheumatism (1973 Jan-Feb); 16 (1): 84-88
	Idson B. Polymers in skin cosmetics. Cosmetics & Toiletries 1988; 103: 63-68.
	Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. Acta Anaesthesiol. Scand. 1985; 29: 736-738.
	Kalbhen D.A. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon®). Z. Rheumatol (1982); 41: 202-211

KRIKORIAN 5/10/95



FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION	N DISCLOSURE CITATION	APPLICANTS	
(Use several	sheets if necessary, MAI	Rudolph E. Falk,	Samuel S. Asculai
	17 17 1995	FILING DATE Jan. 14, 1995	GROUP 1 8.96
	1995	Jan. 14, 1995	124
	ARM ON		


Sh.	Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence. Nippon Rinsho (1968 Jan); 26(1): 89-95
	Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. Transplantation (1984 Feb.); 37(2): 139-145
	McIlwraith W. Current concepts in equine degenerative joint disease. Journal of the American Veterinary Medical Association 1982; February 1: 239-250.
	Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future. Nippon Rinsho (Jan. 1986); 26(1): 61-65
	Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review. The Cornell Veterinarian 1981; 71(4): 355-375.
	Pigman W, et al. Acide hyaluronique et facteurs de perméabilité tissulaire. Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202.
	Pruett RC, Schepens CL, Constable IJ, Swann DA. Hyaluronic acid vitreous substitute. In: Vetreous Surgery and Advances in Fundus Diagnosis and Treatment. Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444.

KRIKORIAN S/10/98

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PT-1039	APPLICATION SERIAL NO. 07/838,675
INFORMATION (Use several	DISCLOSURE CITATION Sheets if necessary)	APPLICANTS Rudolph E. Falk, S	Samuel S. Asculai
	1995 Thou and	FILING DATE Jan. 14, 1995	GROUP 1806 1211

84	Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54.
	Rydell NW, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clinical Orthopaedics and Related Research 1971; 80(October): 25-29.
	Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex. Current Therapeutic Research 1978; 23(4): 455-463.
	Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. Acta Ophthalmol. 1986; 18: 9-13.
	Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: The role of hyaluronic acid. Pharmatherapeutica 1988; 5(4): 233-239.
	Sertoli P, Merello A, Parodi M. L'acido jaluronico, per uso topico, nella cura delle ulcere trofocircolatorie degli arti inferiori. (Comunicazioni). Giornale Italiano di Dermatologia 1970; 45(8): 468-471.
	Walther, M. The Prevention of Strine Cutis Distansae During Pregnancy. Mineva Gynecolgia (1981) Vol. 33: 497-499

KRIKORIAN STOPST



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.

(REV. 8-83) PATENT AND TRADEMARK OFFICE PT - 1039

INFORMATION DISCLOSURE CITATION 17

(Use several sheets if necessary 1595

Filing date Jan. 14, 1995

GROUP

GROUP

1806

1211

GROUP

1806

1211

X

Weirich, E.G., Longauer, J.K., Kirkwood, A.H.

Dermatopharmacology of salicylic acid. III. Topical contrainflammatory effect of salicylic acid and other durgs in animal experiments.

Dermatologica (1976), 152(2): 87-99

EXAMINER

KRIKONIA N

DATE CONSIDERED

5/15/98

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.